Neuland Laboratories Ltd (NEULANDLAB) Q4FY25 Concall Summary - Mar-2025 Qtr
Performance Overview
- Neuland Laboratories experienced a decrease in total income for Q4 FY25, reaching INR 335.8 crores, a 14% decline compared to Q4 FY24.
- Prime and specialty segments were the primary revenue contributors during the quarter.
- EBITDA for Q4 FY25 stood at INR 58.2 crores with a margin of 17.3%, a decrease attributed to business mix, lower revenue, and reduced gross margins.
- For the full fiscal year FY25, total income reached INR 1,497.3 crores, a marginal 4.7% degrowth compared to FY24.
- The company maintains a cautiously optimistic outlook, driven by a robust customer pipeline and the anticipated positive impact of the newly capitalized Unit 3 production block.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.